GRAMD1C

Across TCGA pan-cancer cohorts, GRAMD1C mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of GRAMD1C’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where GRAMD1C mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GRAMD1C is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where GRAMD1C tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRAMD1C mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	−0.709	<.001	8	view →
LSCC	Male	II,III,IV	−1.140	<.001	6	view →
CCRCC	All	All	+0.387	.010	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

GRAMD1C–LUAD

Open the LUAD breakdown →